Related references
Note: Only part of the references are listed.Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes
J. Craig Hartman et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2010)
Endothelin-1 Impairs Alveolar Epithelial Function via Endothelial ETB Receptor
Alejandro P. Comellas et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
Michael A. Weber et al.
LANCET (2009)
Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism
Terence K. Trow et al.
RESPIRATORY MEDICINE (2009)
Endothelin receptor antagonists for pulmonary arterial hypertension - Rationale and place in therapy
Laura C. Price et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2008)
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
N. S. Kirkby et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Endothelin: 20 years from discovery to therapy
Matthias Barton et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2008)
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Christian F. Opitz et al.
EUROPEAN HEART JOURNAL (2008)
Endothelin receptor antagonists in pulmonary arterial hypertension
J. Dupuis et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
Marc Iglarz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist
Paul L. M. van Giersbergen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects
J Dingemanse et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist
J Dingemanse et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions
K Fattinger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Molecular cloning and characterization of the murine bile salt export pump
RM Green et al.
GENE (2000)
Share Paper
